Cardiome Expects Anti-Arrhythmic NDA Submission By 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
In a Phase III study, 52% of patients with recent onset atrial fibrillation converted to normal heart rhythm compared to 4% for placebo. RSD1235 could merit premium pricing over Wyeth’s Cordarone and amiodarone generics, Cardiome CEO says.
You may also be interested in...
FDA Refuses To File Cardiome/Astellas RSD1235 NDA
Cardiome says a third quarter resubmission of its anti-arrhythmic product will not require additional clinical data.
FDA Refuses To File Cardiome/Astellas RSD1235 NDA
Cardiome says a third quarter resubmission of its anti-arrhythmic product will not require additional clinical data.
Cardiome Oxyprim “Approvable” For Gout, But Product’s Future Now In Doubt
FDA requests additional clinical and manufacturing data. Cardiome will “reflect” on FDA’s comments before making a final decision on oxypurinol.